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Abstract 31 
Despite marked advancements in its treatment, breast cancer is still the second leading cause of 32 
cancer death in women, due to relapses and distal metastases. Breast cancer stem cells (CSCs), are a 33 
cellular reservoir for recurrence, metastatic evolution and disease progression, making the 34 
development of novel therapeutics that target CSCs, and thereby inhibit metastases, an urgent need. 35 
We have previously demonstrated that the cystine-glutamate antiporter xCT (SLC7A11), a protein 36 
that was shown to be overexpressed in mammary CSCs and that plays a key role in the maintenance 37 
of their redox balance, self-renewal and resistance to chemotherapy, is a potential target for 38 
mammary cancer immunotherapy. This paper reports on the development of an anti-xCT viral 39 
vaccine that is based on the bovine herpesvirus 4 (BoHV-4) vector, which we have previously 40 
showed to be a safe vaccine that can transduce cells in vivo and confer immunogenicity to tumor 41 
antigens. We show that the vaccination of BALB/c mice with BoHV-4 expressing xCT (BoHV-4-42 
mxCT), impaired lung metastases induced by syngeneic mammary CSCs both in preventive and 43 
therapeutic settings. Vaccination induced T lymphocyte activation and the production of anti-xCT 44 
antibodies that can mediate antibody-dependent cell cytotoxicity (ADCC), and directly impair CSC 45 
phenotype, self-renewal and redox balance. Our findings pave the way for the potential future use 46 
of BoHV-4 vectors that target xCT in metastatic breast cancer treatment.  47 
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Introduction 48 
Breast cancer is a deadly disease that affects millions of women worldwide. Despite advances in 49 
diagnosis and treatment, it is still the second cause of cancer death in women worldwide 
1
. Local 50 
and distant tumor recurrence occurs in a high percentage of patients and metastases are the main 51 
cause of mortality 
2
. Novel therapies to treat metastatic breast cancer therefore become a necessity.  52 
Recurrence and metastatic disease in breast cancer and most solid tumors have been ascribed to a 53 
small cancer cell population with stem-like properties, referred to as cancer stem cells (CSCs) 
3
. 54 
CSCs escape cell cycle regulation and cell death, are endowed with unlimited self-renewal potential 55 
and tumor-initiating capacity as well as expressing epithelial to mesenchymal transition (EMT) 56 
markers, which enable them to migrate and initiate metastases. Moreover, CSCs overexpress many 57 
detoxifying enzymes and possess increased drug efflux and DNA repair capacities, which render 58 
them resistant to radiotherapy and cytotoxic drugs 
4
. Much effort has therefore been dedicated to 59 
identifying novel targets and therapies to specifically impact CSCs 
5
. 60 
We have identified the cystine-glutamate antiporter protein, xCT (SLC7A11), the light chain of the 61 
antiporter system xc
-
, as an oncoantigen (a tumor-associated antigen with a central role in cancer 62 
development and progression 
6
), that is overexpressed in human and mouse mammary CSCs 
7
. xCT 63 
plays an important role in maintaining intracellular redox balance, as it mediates the exchange of 64 
intracellular glutamate with extracellular cystine and thus promotes the synthesis of the anti-oxidant 65 
glutathione (GSH), thereby controlling intracellular reactive oxygen species (ROS), levels and 66 
chemosensitivity 
8
. Moreover, xCT expression creates a reducing extracellular microenvironment, 67 
in a GSH-independent manner, by promoting a redox cycle in which cystine is taken up by cells and 68 
reduced to cysteine, some of which is secreted via constitutively expressed neutral amino acid 69 
transport systems 
9
. Recent evidence shows that xCT also assists in protection from ferroptosis 
8
, 70 
and in cell metabolism regulation 
10
. xCT is only expressed by a few normal cell types (astrocytes, 71 
microglia and some myeloid cells) 
7
, while it is overexpressed in numerous cancers, including a 72 
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high percentage of mammary tumors 
11-15
. xCT expression has been observed in the CSCs of several 73 
cancer types, such as glioblastoma, colorectal, lung and gastric cancers 
16
, where it is stabilized on 74 
the cell membrane via interaction with two stem cell markers, Mucin-1 and CD44v 
17
. xCT is 75 
therefore a promising target for the treatment of many cancers. In fact, research has demonstrated 76 
that xCT down-modulation and inhibition exert antitumor effects by impairing tumor growth and 77 
metastatic dissemination in preclinical models 
18
. Moreover, preclinical experiments have shown 78 
that xCT disruption impairs the ROS defense system and sensitizes CSCs to chemotherapy, 79 
enhancing the therapeutic efficacy of doxorubicin, cisplatin and temozolomide 
7, 19, 20
. This evidence 80 
has led to xCT inhibitors, either used in combination with chemotherapy or alone, being 81 
investigated in a number of clinical trials on cancer patients. The most commonly used xCT 82 
inhibitor is sulfasalazine (SASP), an anti-inflammatory drug approved by the FDA and EMA for the 83 
treatment of inflammatory bowel disease, ulcerative colitis and Crohn's disease. However, SASP is 84 
poorly bioavailable, induces many side effects and is not xCT specific, since it also inhibits NF-kB 85 
in vivo 
21
. This may explain why clinical trials involving SASP administration have not produced 86 
the expected results.  87 
Our search for new means to disrupt xCT functionality in CSCs has focused on active 88 
immunotherapy; anti-cancer vaccines are a promising strategy, as suggested by the advanced 89 
clinical testing that several have undergone in recent years
22, 23
 
24
. We have previously demonstrated 90 
that a DNA-based vaccine that expresses the full-length murine (m)xCT protein 
7
, and a virus-like 91 
particle, which displays the sixth extracellular loop of human xCT 
25
, induce an anti-xCT humoral 92 
response in BALB/c mice that was able to impair murine and human mammary CSC self-renewal in 93 
vitro and hinder mammary tumor growth and lung metastases in syngeneic tumor models. We 94 
herein explore Bovine Herpes Virus-4 (BoHV-4) use as a viral vector to deliver the full length xCT 95 
DNA, as we have previously demonstrated it is superior to DNA vaccination in inducing an anti-96 
HER2 antibody response in tolerant HER2 transgenic BALB-neuT mice 
26
. Moreover, BoHV-4 97 
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vaccination has the potential to induce an immune response against various xCT epitopes as our 98 
DNA vaccine, but does not require electroporation, avoiding the use of anesthetics and concerns 99 
about patients’ compliance. 100 
The immunization of mice with a BoHV-4 vector that expresses the full-length mxCT protein 101 
(BoHV-4-mxCT), induces T lymphocyte activation and the production of anti-xCT antibodies that 102 
can target CSCs both directly, by impairing self-renewal and increasing ROS content and 103 
ferroptosis, and via the induction of antibody-dependent cell cytotoxicity (ADCC). This immune 104 
response inhibited lung metastases that were either generated by the injection of CSCs derived from 105 
HER2/neu
+
 TUBO 
27
, or from triple negative 4T1 mammary cancer cells in syngeneic BALB/c 106 
mice, in preventive and therapeutic settings, respectively. 107 
Results 108 
Generation of a recombinant virus that delivers mxCT expression cassette 109 
An optimized open reading frame (ORF), coding for mxCT (Slc7a11), was customized by adding a 110 
33 aa peptide tag, derived from bovine herpesvirus-1 glycoprotein D (gD106) 
28
 (Supplementary Fig. 111 
1A), to its C-terminal to generate mxCTgD106 ORF. mxCTgD106 ORF was located downstream of 112 
the CMV promoter and upstream of the growth hormone polyadenylation signal to give the CMV-113 
mxCTgD106 expression cassette, whose functionality was tested via western blotting with a mAb to 114 
gD106. CMV-mxCTgD106 was excised from the plasmid backbone and sub-cloned into the pINT2 115 
shuttle vector, which contained two BoHV-4 TK flanking sequences 
29
 (pTK-CMV-mxCTgD106-116 
TK), to generate pINT2-CMV-mxCTgD106. This construct's protein expression was validated by 117 
transient transfection into HEK293T cells and immunoblotting (Supplementary Fig. 2). A genomic 118 
molecular clone, obtained from a BoHV-4 that was isolated from the milk cell fraction of a 119 
clinically healthy cow (designated as BoHV-4-A) 
30
, was used to generate the BoHV-4-A-CMV-120 
mxCTgD106 recombinant virus; pINT2-CMV-mxCTgD106 was linearized and electroporated into 121 
SW102 E. coli cells that contained the artificial chromosome pBAC-BoHV-4-A-KanaGalKΔTK 30-122 
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36
 (Fig. 1A), and heat-induced homologous recombination 
37
, generated pBAC-BoHV-4-A-CMV-123 
mxCTgD106. The TK locus of the BoHV-4 genome was chosen for its extreme stability after 124 
repeated in vitro and in vivo passages, and because it is reliable when integrating foreign DNA 125 
sequences into the BoHV-4 genome without any transgene or viral replication efficiency loss due to 126 
recombination. Viral particles were generated from pBAC-BoHV-4-A-CMV-mxCTgD106, and the 127 
replication properties of BoHV-4-mxCT were compared to those of the parental BoHV-4-A virus. 128 
The replication rate of BoHV-4-mxCT is slightly lower than in BoHV-4-A (Fig. 1 D). However, 129 
BoHV-4-mxCT-transduced cells expressed mxCT, as revealed by western blotting (Fig. 1 E). A 130 
virus expressing the unrelated A29 Monkey poxvirus glycoprotein (BoHV-4-A29)
38
 was used as a 131 
control.  132 
BoHV-4-mxCT vaccination induces an anti-xCT humoral response  133 
Sera from BoHV-4-mxCT- and BoHV-4-A29-vaccinated mice were collected, as was untreated 134 
mouse sera, 2 weeks after the last vaccination, and tested by ELISA. Figure 2A shows that BoHV-135 
4-mxCT induced an antibody response against the mxCT protein. The sera were tested in ELISA for 136 
their ability to bind the extracellular portions of xCT to better evaluate the therapeutic potential of 137 
these antibodies. Fig. 2B-F demonstrates that BoHV-4-mxCT-induced antibodies recognized the 138 
extracellular domains of mouse xCT. Sera from BoHV-4-A29-vaccinated mice also bound, with a 139 
lower affinity, to full length mouse xCT and to its 6
th
 extracellular loop (Fig. 2A, F), which could be 140 
explained by the identity of 3 residues in A29 and xCT 6
th
 extracellular loop, which is sufficient to 141 
induce cross-reactivity 
39
. BoHV-4-mxCT induced antibodies also recognized xCT protein in its 142 
native conformation, as shown by the decoration of xCT
+
 tumorspheres by BoHV-4-mxCT-143 
vaccinated mice sera (Fig. 2G). Finally, this binding ability resulted in the activation of ADCC 144 
against xCT
+
 tumor cells, as demonstrated by incubating 4T1 target cells with the sera of BoHV-4-145 
mxCT vaccinated mice in the presence of splenocytes from unvaccinated mice (Fig. 2H). 146 
BoHV-4-mxCT-induced antibodies target CSCs and impair xCT function  147 
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To evaluate the direct effect exerted by BoHV-4-mxCT-induced antibodies on mammary CSCs, 148 
TUBO-derived tumorspheres were incubated for 5 days with sera from either control or vaccinated 149 
mice, or with the xCT inhibitor SASP (control). Whereas sera from untreated or BoHV-4-A29 150 
vaccinated mice did not induce tumorsphere alterations, in terms of morphology, sphere number 151 
and dimension as compared with tumorspheres grown in medium alone, sera from mice vaccinated 152 
with BoHV-4-mxCT induced a reduction in sphere number and dimension. Tumorsphere dimension 153 
was further decreased by SASP treatment, suggesting that it is very efficient in slowing 154 
tumorsphere growth (Fig. 3A-C). BoHV-4-mxCT and SASP effects on tumorsphere generation 155 
were accompanied by a slight inhibition in cell cycle progression, as demonstrated by the increase 156 
in quiescent cells in the G0/G1 phase, when compared with control cells (Fig. 3D). BoHV-4-mxCT 157 
sera and SASP seemed to be able to target CSCs as they lowered the percentage of cells positive for 158 
the Aldefluor reagent, a non-immunological method to identify CSCs on the basis of their aldehyde 159 
dehydrogenase-1 (ALDH) activity (Fig. 3E, F). Indeed, high ALDH expression is considered a 160 
marker of CSC of various lineages, including breast cancer 
40
. Moreover, both SASP and, to a 161 
greater extent, sera from BoHV-4-mxCT-treated mice altered CSC redox balance, inducing an 162 
intracellular ROS accumulation (Fig. 3G, H). The ROS content increase in cells treated with BoHV-163 
4-mxCT-vaccinated mice sera or SASP was accompanied by an increase in ChaC glutathione-164 
specific gamma-glutamylcyclotransferase 1 (Chac1) mRNA content (Fig. 3I), which is significantly 165 
elevated in cells undergoing endoplasmic reticulum stress and ferroptosis 
8
. Interestingly, BoHV-4-166 
mxCT-vaccinated mice sera and, to a greater extent, SASP, also upregulated xCT mRNA (Fig. 3L). 167 
Overall, these results indicate that BoHV-4-mxCT vaccination induces the production of antibodies 168 
that alter CSC self-renewal and redox balance. These results were not confined to the TUBO model, 169 
since sera from BoHV-4-mxCT-vaccinated mice also reduced tumorsphere self-renewal, increased 170 
ROS content and decreased Aldefluor
+
 CSC number in 4T1 cells (Fig. 3M-O). Moreover, BoHV-4-171 
mxCT-induced antibodies and, to a greater extent, SASP significantly inhibited glutamate export by 172 
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4T1 tumorspheres, reducing the amount of glutamate in the supernatant of treated tumorspheres to 173 
levels similar to those in epithelial 4T1 parental cells (Fig. 3P). 174 
Interestingly, BoHV-4-mxCT-induced antibodies cross-reacted with human xCT, decreased CSC 175 
self-renewal and increased ROS content in human HER2
+
 SKBR3 breast cancer cells 176 
(Supplementary Fig. 3). 177 
Vaccination with BoHV-4-mxCT prevents TUBO lung metastases 178 
To test the BoHV-4-mxCT-induced immune response's ability to prevent mammary CSC seeding in 179 
lungs, BALB/c mice were vaccinated twice, at two-week intervals, with BoHV-4-mxCT, or BoHV-180 
4-A29 or left untreated (negative controls). After 7 days, mice were injected intravenously (i.v.), 181 
with syngeneic CSC-enriched 
27
, xCT
+
 TUBO tumorsphere-derived cells 
7
, and lung metastasis 182 
number was evaluated three weeks later. Whereas lungs from untreated and BoHV-4-A29-183 
vaccinated mice showed a high number of macrometastases, lungs from BoHV-4-mxCT-vaccinated 184 
mice only displayed isolated macrometastases, as shown in Fig. 4A. These results were confirmed 185 
in a micrometastases analysis in H&E-stained lung sections (Fig. 4B), in which BoHV-4-mxCT-186 
vaccinated mice showed a significant decrease in the percentage of lung tissue occupied by 187 
metastases (Fig. 4C), and in the number of metastases per square mm (Fig. 4D), relative to control 188 
mice. Overall, these data indicate that BoH-V-4-mediated xCT immunotargeting prevents 189 
mammary CSC seeding in the lungs. 190 
Vaccination with BoHV-4-mxCT reduces mammary cancer growth and metastatic 191 
dissemination in a therapeutic setting 192 
To investigate the ability of therapeutic vaccination to reduce tumor growth and spontaneous lung 193 
metastatization in mice with existing tumors, 4T1 tumorsphere-derived cells were transplanted 194 
subcutaneously (s.c.) into mice. When s.c. tumors reached 2 mm mean diameter, mice were 195 
vaccinated twice, at two week intervals. Tumor growth rate, measured as tumor volume progression 196 
over time, was significantly lower in the BoHV-4-mxCT vaccinated group than in the untreated and 197 
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BoHV-4-A29 vaccinated groups (Fig. 4E). Mice were culled, lungs harvested and subsequently 198 
histologically analyzed twenty days after tumor cell challenge. BoHV-4-mxCT significantly 199 
reduced the percentage of metastatic area and spontaneous micrometastasis number in the lungs 200 
(Fig. 4F-H), suggesting that vaccination with BoHV-4-mxCT may be a new approach to mammary 201 
cancer treatment. 202 
BoHV-4-mxCT induces T lymphocyte activation in the lungs of vaccinated mice. 203 
To further characterize the immune mechanisms that mediate BoHV-4-mxCT anti-metastatic 204 
potential, the immune cell infiltrate in the lungs of vaccinated mice was analyzed three weeks after 205 
TUBO-derived tumorsphere i.v. injection. CD11b
+
 Ly6G
+
 neutrophils and granulocytic myeloid-206 
derived suppressor cells (gMDSC) were the predominant myeloid cell population in metastatic 207 
lungs, while CD11b
+
Ly6C
+
 monocytic myeloid-derived suppressor cells (mMDSC), CD11b
+ 
208 
F4/80
+ 
macrophages and CD11c
+
 dendritic cells only represented a minority. However, no 209 
significant differences in myeloid cell population proportions were observed in the treatment groups 210 
(Fig. 5A). The percentages of T lymphocytes (CD3
+
), and Natural Killer (NK, CD3
-
CD49b
+
), cells 211 
among the CD45
+
 leucocytes did not vary significantly (Fig. 5B, G), and most T cells were CD4
+
. 212 
No significant CD4
+
/CD8
+
 T cell ratio alterations were detected, although both BoHV-4-A29 and 213 
BoHV-4-mxCT slightly increased the CD8
+
 cell percentage in the CD3
+
 T cell population (Fig. 5C). 214 
Interestingly, BoHV-4-mxCT vaccination induced T cell activation, as suggested by the significant 215 
increase in CD69
+
 cells in the total CD3
+
 T cell population (Fig. 5D), and in both CD4
+
 T helper , 216 
and CD8
+
 T cytotoxic cells (Fig. 5D, H). Moreover, BoHV-4-mxCT significantly increased the 217 
expression of immune checkpoint and exhaustion marker molecule PD1 in CD4
+
, CD8
+
 T and NK 218 
cells (Fig. 5E, H). These data suggest that BoHV-4-mxCT vaccination may benefit from association 219 
with anti-PD1 and/or anti-PDL1 monoclonal antibody therapy. In fact, PDL1 was expressed by a 220 
small percentage of epithelial and myeloid cells in the lungs, and BoHV-4-A29 and BoHV-4-mxCT 221 
vaccination slightly increased its expression in epithelial cells (Fig. 5F).  222 
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BoHV-4-mxCT vaccination induces the generation and expansion of effector T lymphocytes 223 
To further characterize the T cell response induced by BoHV-4-mxCT vaccination, spleens from 224 
vaccinated mice that did not receive tumor cell injection were harvested and T cells were evaluated 225 
for their response against xCT. When splenocytes were re-stimulated with 15 μg/ml of H-2Kd 226 
dominant mouse xCT (S Y A E L G T S I) peptide 
7
, no specific IFN- production was detected by 227 
ELISPOT (data not shown), suggesting that high-avidity CD8
+ 
T-cell clones could have been 228 
depleted during thymic selection, as we have previously reported for the Her2 antigen in the BALB-229 
neuT model 
41
. However, when splenocytes were cultured overnight with MitomycinC-treated xCT
+
 230 
4T1 cells, an increase in the percentage of CD4
+
 T cells expressing the CD69 activation marker was 231 
observed in BoHV-4-mxCT splenocytes (Fig. 6A), accompanied by a statistically significant 232 
increase in IFN--producing helper T cells and a trend of increase in CD107+ cytotoxic CD4+ T 233 
cells (Fig. 6B, C). Activation and IFN- production were higher in CD8+ T cells from BoHV-4-234 
mxCT vaccinated mice than in the untreated mice (Fig. 6D-F). The increased activation and IFN- 235 
production of both CD4
+
 and CD8
+
 T cells was maintained after 5 days of co-culture with 4T1 cells, 236 
when a statistically significant increase in CD107
+
 cytotoxic cells was also observed (Fig. 6G-N). 237 
To test the ability of these activated T cells to induce cytotoxicity in 4T1 cells, an in vitro killing 238 
assay was performed by co-culturing effector splenocytes from control, BoHV-4-mxCT and BoHV-239 
4-A29 vaccinated mice with CFSE-labeled 4T1 target cells for 48 hours. BoHV-4-A29 and BoHV-240 
4-mxCT splenocytes displayed enhanced lytic activity compared to untreated-mice splenocytes, but 241 
only a mild increase in BoHV-4-mxCT splenocyte cytotoxic activity over that of BoHV-4-A29 was 242 
observed (Fig. 6O). 243 
To evaluate in vivo the role of this vaccine-induced T cell response, vaccinated and control mice 244 
were depleted of CD4
+
 and CD8
+
 T cells, starting at the time of TUBO tumorsphere i.v. injection 245 
(Fig. 7). While no significant differences in the percentage of metastatic area (Fig. 7A) and the 246 
number of lung metastases (Fig. 7B) were found in untreated and BoHV-4-A29 vaccinated mice 247 
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following depletion, a significant increase in both parameters was observed in CD8
 
depleted mice 248 
vaccinated with BoHV-4-mxCT (Fig. 7A, B). A significant increase in the percentage of metastatic 249 
area was also found in CD4 depleted BoHV-4-mxCT vaccinated mice as compared to not-depleted 250 
vaccinated mice (Fig. 7A). Since we have previously shown that CSC-enriched TUBO 251 
tumorspheres downregulated MHC class I expression 
42
, we hypothesized that BoHV-4-mxCT-252 
induced antibodies could induce their differentiation and subsequent MHC class I expression. To 253 
confirm this hypothesis, TUBO tumorspheres were cultured for 5 days in the presence of sera from 254 
untreated, BoHV-4-A29 or BoHV-4-mxCT vaccinated mice or with IgG purified from the sera of 255 
BoHV-4-mxCT vaccinated mice. As shown in Fig. 7C, both purified IgG and sera from BoHV-4-256 
mxCT vaccinated mice induced a significant increase in MHC class I expression, as compared to 257 
the control conditions. However, MHC class I upregulation induced by BoHV-4-mxCT sera was 258 
significantly higher than that induced by purified IgG, suggesting that the effect of anti-xCT IgG is 259 
amplified by the presence of vaccination-induced cytokines. Sera from BoHV-4-mxCT vaccinated 260 
mice induced also a mild increase in MHC class II and Fas expression (Fig. 7C). It is thus 261 
conceivable that CD4
+
 and, to a greater extent, CD8
+
 cytotoxic T cells contribute to the anti-262 
metastatic effects of BoHV-4-mxCT vaccination.  263 
264 
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Discussion 265 
The recent clinical successes of checkpoint blocking antibodies and the discovery of cancer 266 
neoantigens have renewed interest in immunotherapy, which is entering a golden age. However, 267 
therapeutic cancer vaccines have not yet provided the expected clinical results, which would 268 
intensify the search for better tumor antigens and vaccine formulations. Moreover, the discovery 269 
that CSCs are the main source of tumor recurrence highlights how developing vaccines towards 270 
CSC-expressed antigens may treat metastatic cancer. We have previously shown that xCT is 271 
overexpressed in breast CSCs, where it plays a key role in the maintenance of self-renewal and 272 
redox balance 
7
, making it a potential CSC oncoantigen. In physiological conditions, xCT 273 
expression is confined to specialized areas in the brain, spleen and thymus 
43
, while its expression is 274 
enhanced on tumor cells in pancreatic, gastrointestinal, glioblastoma and colorectal cancers 
7
. 275 
Indeed, xCT provides increased antioxidant capability allowing cancer cells to grow and resist to 276 
chemo- and radiotherapy 
20
. Therefore, in several cancers, increased xCT expression is predictive 277 
for poor survival 
11
, making its immune-targeting of great clinical interest.  278 
We have previously demonstrated that xCT immune-targeting, by means of VLPs or DNA 279 
vaccination, induced a specific humoral response that hampered breast cancer growth and 280 
metastasis in preclinical models of triple negative and HER2
+
 breast cancers. However, these 281 
immunotherapies did not induce specific T cell activation, since xCT is a self-tolerated antigen and 282 
thymic depletion of high-avidity T-cell clones can occur 
7, 25
. 283 
This work has focused on viral-vectors as a means to breaking tolerance and inducing a strong 284 
immune response, and has developed a BoHV-4-based vaccine that targets xCT. We have 285 
previously demonstrated that BoHV-4 can be used to express exogenous antigens in various cell 286 
types in several animal species without pathogenicity or oncogenicity 
32, 44
. Moreover, when 287 
engineered to express HER2-derived antigens, it can protect HER2 transgenic BALB-neuT mice 288 
from autochthonous mammary cancer 
26
. 289 
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A mouse xCT-expressing BoHV-4 vector was thus generated to inhibit the seeding of HER2
+
 CSCs 290 
to the lungs in BALB/c mice, preventing the formation of pulmonary metastases. Of greater clinical 291 
interest is BoHV-4-mxCT's ability to decrease the cancer growth, spontaneous metastatic spreading 292 
and lung metastasis formation induced by TNBC CSCs in a therapeutic setting, suggesting that it 293 
may benefit the 30% of TNBC patients who display xCT expression 
11
.  294 
Cancer metastasis formation is a complex, multistage event involving continuous and finely tuned 295 
interplay between the microenvironment and cancer cells, while immune cell composition in the 296 
target organ is key in metastatic cell seeding 
6, 45
. BoHV-4-mxCT vaccination induced activated T 297 
lymphocyte recruitment in metastatic lungs, and increased the percentage of CD4
+
 and CD8
+ 
T cells 298 
that secreted IFN-γ in response to re-stimulation with xCT+ tumor cells. This is noteworthy because 299 
T lymphocyte infiltration is associated with good prognosis in breast cancer patients, while the 300 
activation of IFN-γ-producing T helper 1 and CD8+ T cells is important for anti-cancer response 46. 301 
The re-stimulation of splenocytes from BoHV-4-mxCT vaccinated mice with 4T1 cells also 302 
increased the percentage of CD107
+
 T cells. Nevertheless, only a very slight increase in the ability 303 
of splenocytes to kill 4T1 cells in vitro was detected when compared with splenocytes from BoHV-304 
4-A29 control mice. Since CSCs down regulate MHC class I expression as an immune evasion 305 
mechanism 
42
, CD8
+
 cytotoxic T lymphocytes are only expected to play a marginal role in the 306 
immune surveillance of CSC metastatic spreading. This was confirmed by the absence of any effect 307 
of CD8 depletion in untreated and BoHV-4-A29 vaccinated mice. A different situation is found 308 
after BoHV-4-mxCT vaccination. Indeed, the induction of a T helper 1 response by BoHV-4-mxCT 309 
was accompanied by a specific humoral response, including polyclonal antibodies that can 310 
recognize xCT extracellular loops and bind CSC-enriched tumorspheres. These anti-xCT antibodies 311 
exert therapeutic activity through different mechanisms, one of which is induction of CSC 312 
differentiation and MHC class I expression, which makes them sensitive to CD8
+
 T cell killing. 313 
Indeed, depletion of CD8
+
 T cells in BoHV-4-mxCT vaccinated mice resulted in an increased 314 
15 
 
development of lung metastases after an i.v. challenge of TUBO tumorspheres. The T helper 1 315 
response potentiates this effect through the release of IFN- that induces MHC class I expression. 316 
Moreover, this cytokine has been shown to induce MHC class II expression in cancer cells in 317 
TNBC and other tumors with a T cell infiltrate 
46
. Indeed, in our model the sera from BoHV-4-318 
mxCT vaccinated mice led to upregulation of MHC class II expression in TUBO tumorspheres, and 319 
CD4
+
 cells depletion during the effector phase of vaccine-induced immune response slightly 320 
increased metastasis growth. This suggests the participation to immune response of CD4
+ 
cytotoxic 321 
T lymphocytes, a cell population recently shown to lyse infected and neoplastic cancer cells in an 322 
MHC class II dependent manner 
47
. 323 
Vaccine-induced anti-xCT antibodies participate in tumor cell elimination by activating the innate 324 
immune response via ADCC induction. Moreover, they can directly impair CSC self-renewal and 325 
arrest their cell cycle in the G1 phase. BoHV-4-mxCT-induced antibodies alter CSC redox balance 326 
by targeting xCT, which consequently increases intracellular ROS levels. Elevated ROS levels 327 
hamper CSC survival by decreasing β-catenin activation and consequently down-regulating stem 328 
cell genes, causing enhanced sensitivity to T cell cytotoxicity, as discussed above, chemo- and 329 
radiotherapy, and ferroptosis; a recently discovered form of cell death caused by ROS and iron-330 
dependent lipid peroxide accumulation 
48
. Indeed, elevated levels of the endoplasmic reticulum 331 
stress and ferroptosis marker Chac1 
8
, were observed in CSCs treated with sera from BoHV-4-332 
mxCT-vaccinated mice, confirming that this mechanism may contribute to BoHV-4-mxCT anti-333 
metastatic effect.  334 
Moreover, as xCT mediates glutamate export in exchange with cystine, BoHV-4-mxCT-induced 335 
antibodies lower extracellular glutamate levels. This makes the BoHV-4-mxCT vaccine an 336 
interesting tool for the treatment of patients with bone metastasis, a common characteristic of 337 
advanced breast cancer, since it has been demonstrated that glutamate released by cancer cells can 338 
disrupt normal bone turnover, favoring metastasis formation and possibly causing cancer-induced 339 
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bone pain 
49
. Moreover, high levels of extracellular glutamate have recently been shown to drive 340 
invasion through a paracrine signaling mediated by metabotropic glutamate receptors expressed in 341 
breast cancer cells 
50
.  342 
Although xCT is a self-antigen, no overt adverse effects were observed in mice vaccinated with 343 
BoHV-4-mxCT, probably because its physiological expression is restricted to a few central nervous 344 
system and myeloid compartment cell types 
7, 51
. The feasibility of xCT targeting in patients is 345 
supported by the extended usage of its inhibitor SASP in the clinical practice, for the treatment of 346 
many inflammatory diseases, without serious adverse events. Moreover, the safety of xCT immune 347 
targeting is further supported by the lack of immune infiltrate and abnormalities in the brains of 348 
mice vaccinated with VLPs that present xCT extracellular loops 
25
, and by the fact that xCT 349 
knockout mice display normal development and no organ alterations 
52
. 350 
A comparison of the immune responses induced by BoHV-4-mxCT and by the DNA- and VLP-351 
based vaccines we have previously used to target xCT requires additional experiments. However, 352 
from the data already available, it is clear that in all cases the main effector mechanism is 353 
represented by a T helper 1 immune response that results in anti-xCT IgG production 
7, 25
. The 354 
highest specific antibody titer evaluated by ELISA was obtained with VLP vaccines, whose 355 
limitation - or advantage - is represented by the relatively small dimension of the xCT derived 356 
peptides they can display 
53
. Instead, both DNA and BoHV-4 vaccines were designed to express the 357 
full length xCT protein, allowing the production of antibodies directed against different portions of 358 
xCT 
53
. Moreover, while no specific T cell responses were detected in DNA and VLP vaccinated 359 
mice (even if no in vivo depletion experiments were performed) 
7, 25
, BoHV-4-mxCT induced a 360 
CD8 cytotoxic response, with a key role in vivo. This suggests that active immunization can be 361 
more effective than the passive administration of anti-xCT antibodies. Finally, despite inducing not 362 
completely identical immune responses, the anti-tumor and anti-metastatic efficacy of the three 363 
vaccines is very similar 
7, 25
. This observation suggests that xCT immunotargeting, independently 364 
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on the vector used, slows tumor growth and decreases metastasis formation but is not able to 365 
completely eradicate the disease. Therefore, anti-xCT vaccination should be combined with other 366 
anti-cancer strategies. Indeed, it has become ever clearer that combination therapies provide better 367 
patient survival results than single agents. xCT immune-targeting may be used as an add-on therapy 368 
together with conventional and innovative treatments that can further stimulate immune responses 369 
targeting differentiated cancer cells/CSCs. Combinations with anti-PD1 or PD-L1 monoclonal 370 
antibodies may improve therapeutic efficacy as BoHV-4-mxCT enhances activation and 371 
consequently PD-1 expression on infiltrating T lymphocytes and we showed that PD-L1 is 372 
expressed on both CSCs and myeloid cells. The administration of anti-PD1 and anti-PD-L1 373 
antibodies to breast cancer patients is currently undergoing clinical trial, and preliminary data show 374 
clinical activity in some TNBC patients treated with the anti-PD1 Pembrolizumab, (Keytruda; 375 
Merck; NCT01848834), and the anti-PD-L1 Atezolizumab (Tecentriq; Roche). Moreover, xCT 376 
targeting could be successfully coupled with chemotherapy, since many chemotherapeutic drugs 377 
eliminate differentiated cancer cells but expand CSCs by inducing a hypoxia-inducible factor (HIF)-378 
1–dependent increase in xCT, leading to increased GSH and subsequent mitogen-activated protein 379 
kinase (MEK), inhibition and FoxO3 activation, which induces the transcription of Nanog and other 380 
stem-cell related genes 
54
. In fact, we have previously demonstrated that combining anti-xCT DNA 381 
vaccination with doxorubicin significantly enhanced the anti-metastatic potential of the single 382 
treatments 
7
. Since different signaling and metabolic pathways contribute to the maintenance of 383 
CSC phenotype and CSCs present a high degree of plasticity 
4
, another intriguing possibility would 384 
be a combination of multiple CSC-directed therapies to improve CSC elimination and prevent 385 
resistant clone onset. Using xCT immunotherapy together with metformin, a drug used to treat type 386 
2 diabetes currently undergoing clinical trials in breast cancer patients, may exert a synergistic 387 
effect as xCT inhibition fosters the tricarboxylic acid (TCA) cycle by increasing intracellular 388 
glutamate levels, making cancer cells more resistant to glucose starvation 
10
. This negative effect 389 
can be hindered by metformin's inhibition of the TCA cycle and mitochondrial respiration 
55
. 390 
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In conclusion, we have demonstrated that xCT immune-targeting via BoHV-4 based vectors is a 391 
safe strategy with which to target mammary CSCs and impair tumor growth and metastatic spread, 392 
making it a potential candidate for the further development of combination therapies that aim to 393 
prevent recurrence in breast cancer patients. 394 
 395 
Materials and Methods: 396 
Cell and tumorsphere cultures. 4T1 and SKBR3 cells were purchased from ATCC. TUBO cells 397 
were cultured as in 
27
. Cells tested negative for mycoplasma 
56
, were passaged for fewer than 6 398 
months. Tumorspheres were generated as in 
27
, and used at the second passage (P2), except where 399 
otherwise specified. Bovine embryo kidney cells (BEK), were provided by Dr. M. Ferrari, Istituto 400 
Zooprofilattico Sperimentale, Brescia, Italy; (BS CL-94). BEK cells that expressed cre recombinase 401 
(BEKcre), and HEK293T cells were cultured as in 
32
.  402 
Generation of BoHV-4-mxCT. See Supplementary methods for details. Briefly, synthetic Mouse 403 
xCT ORF was amplified from SLC7a11 pDREAM 2.1 (GenScript), via PCR and cloned into the 404 
pIgKE2BVD3gD106 intermediate shuttle vector to generate CMV-mxCTgD106 and then into pINT2-405 
CMV-mxCTgD106. EcoRI-linearized pINT2-CMV-mxCTgD106 was used for heat-inducible 406 
homologous recombination in SW102 E. coli that contained the pBAC-BoHV-4-A-TK-KanaGalK-407 
TK genome targeted to the TK locus with the KanaGalK selector cassette, as in 
37
. Selected SW102 408 
E. coli clones carrying pBAC-BoHV-4 recombinants were analyzed using HindIII restriction 409 
enzyme digestion and Southern blotting with a probe directed to the mxCT sequence 
57
. BAC DNA 410 
(5 μg), was electroporated into BEK and BEKcre cells which were left to grow until the cytopathic 411 
effect (CPE), appeared. BoHV-4-mxCT and control BoHV-4-A29 were propagated by infecting 412 
BEK. Once CPE affected the majority of the cells, the virus was prepared by freezing and thawing 413 
cells three times before the virions were pelleted, using a 30% sucrose cushion 
58
, and then 414 
resuspended in EMEM.  415 
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FACS analysis  416 
Tumorsphere-derived cells were stained using the Aldefluor kit (Stem Cell Technologies) 
42
, or with 417 
anti-H-2Kd-FITC, anti-Fas-PE/Cy7 (BD Bioscience), and anti-MHC class II-APC (Miltenyi Biotec) 418 
as in 
42
. ROS content was measured using 2′,7′-dihydrochlorofluorescein diacetate (DHCF-DA, 419 
Sigma-Aldrich) 
7. Cells were incubated with 100μg/ml RNase A and 50μg/ml propidium iodide 420 
(Sigma-Aldrich) for 30 min for cell cycle analysis 
59
. For immune infiltrate investigations, single 421 
cell suspensions were derived from vaccinated mice lungs 
60
, then stained with anti-CD45-422 
VioGreen, anti-CD3-FITC, anti-CD4-APC-Vio770, anti-CD8-VioBlue, anti-CD49b-PE, anti-PD1-423 
APC, anti-F4/80 -/Vio770, anti-CD11b-FITC, anti-Ly6G-Vioblue, anti-Ly6C-APC/Vio770 424 
(Miltenyi Biotec), anti-CD69-PE/Vio770 (Biolegend), and anti-PDL1-PE (BD Bioscience), as in 
61
. 425 
Samples were acquired on a BD FACSVerse and analyzed using BD FACSSuite software. 426 
CD107 degranulation and IFN- production Assay  427 
4T1 cells were incubated with 50µg/ml MitomycinC (Sigma-Aldrich), at 37°C for 2 hours, then 428 
washed 4 times and cultured overnight or for 5 days in RPMI10%FBS at 1x10
5
 cells/well with 429 
1x10
6 
splenocytes recovered from untreated and vaccinated mice. In the last 4 hours, anti-430 
CD107a/b-FITC Abs (BD Bioscience), and 10µg/ml brefeldinA (Sigma-Aldrich), were added. Cells 431 
were stained for surface antigens, fixed/permeabilized with the BD Cytofix/Cytoperm kit and 432 
stained with anti-IFN--APC (BD Bioscience). Analyses were performed on CD45+-gated 433 
lymphocytes with subsequent gating on either CD4
+
 or CD8
+
. Gates were set on T lymphocytes that 434 
had not been treated with brefeldinA and FMO samples 
62
.  435 
Immunofluorescence 436 
Tumorspheres were cytospinned to glass slides and stained with mouse sera (1:50), as in 
7
, and 437 
nuclei were stained with DAPI (Sigma-Aldrich). Images were acquired on a TCS-SP5II confocal 438 
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microscope and analyzed using LASAF software (Leica). Fluorescence was quantitated using 439 
ImageJ and integrated density was normalized to nuclei number.  440 
ELISA  441 
Antibody responses were evaluated on plates coated with either mouse xCT protein (Cloud-Clone 442 
Corp., 40 ng/well), human xCT protein (Abnova, 30 ng/well), or mouse xCT extracellular loop 443 
peptides (GenScript, 1 µg/well). After blocking with 1%milk (Blotto, SantaCruz Biotechnology), 444 
for 2 hours at 37°C, mouse sera (1:50), were incubated for 2 hours at 37°C. A standard curve was 445 
generated for xCT proteins using a rabbit anti-xCT antibody (ThermoFisher). After 5 washes, HRP-446 
conjugated-anti-mouse and anti-rabbit IgG Abs (Sigma-Aldrich; 1:2,000), were incubated for 1 447 
hour at 37°C. TMB (Sigma-Aldrich), was added after 5 washes. The reaction was stopped using 2N 448 
HCl, and O.D. was measured at 450 nm using a 680XR microplate reader (BioRad).  449 
Glutamate quantification  450 
Glutamate was quantified in supernatants from 4T1 tumorspheres cultured for 5 days with mouse 451 
sera (1:50), or SASP or from 4T1 cells using the Amplex Red glutamic acid/glutamate oxidase 452 
assay kit (ThermoFisher), and was normalized to cell density.  453 
ADCC 454 
1×10
4
 4T1 target cells were stained with 2 µM CFSE (Molecular Probes), cultured overnight with 455 
untreated BALB/c mice splenocytes, used as effector cells (200:1, 100:1, and 50:1 E:T ratio), and 456 
vaccinated mice sera (1:50). Cells were stained with 1μg/ml 7-AAD (BD Bioscience), and acquired 457 
using FACS. %ADCC for each serum was calculated as in 
25
. 458 
In vitro cytotoxicity 459 
1×10
4
 CFSE-labelled 4T1 target cells were incubated with splenocytes from untreated or vaccinated 460 
mice as effector cells (200:1, 100:1, and 50:1 E:T ratio) for 48 hours, then harvested, stained with 461 
1μg/ml 7-AAD, and acquired using FACS, as for ADCC. 462 
21 
 
Immune sera effects on tumorsphere formation 463 
P1 tumorspheres were dissociated and either cultured with immunized mice sera (1:50), 50µM 464 
SASP or nothing. After 5 days, P2 tumorspheres were imaged using a ApoTome fluorescence 465 
microscope (Zeiss), and sphere diameter was measured using AxioVision 4.8 software 
63
. Spheres 466 
were counted, dissociated and processed for FACS analysis.  467 
RNA extraction and qPCR  468 
Total RNA was isolated from TUBO and 4T1 tumorspheres after 5 days of incubation with mouse 469 
sera or SASP, and retrotranscribed to cDNA as in 
27
. qPCR was performed with commercial 470 
Slc7a11 and Gapdh (QuantiTect Primer Assay; Qiagen), or Chac1 custom primers 
8
, as in 
27
. 471 
Slc7a11 and Chac1 expression levels were normalized on Gapdh, and expression levels were 472 
calculated, relative to spheres incubated with untreated sera, using the comparative Ct method 473 
and expressed as fold change. 474 
In vivo treatment 475 
Female 6-week-old BALB/c mice (Charles River Laboratories), were maintained at the Molecular 476 
Biotechnology Center, University of Torino, in accordance with University Ethical Committee 477 
guidelines and European Directive 2010/63. Vaccination, performed before (preventive model), or 478 
after tumor challenge (therapeutic model), consisted of two i.p. injections of 10
6
 TCID50 of either 479 
BoHV-4-A29 or BoHV-4-mxCT at a 2-week interval. Two weeks after the second vaccination, 480 
blood and spleens were collected from some mice, while others had 5x10
4 
TUBO-tumorsphere 481 
derived cells injected i.v. and their lungs explanted 20 days later 
7
. In the T cell depletion 482 
experiment, mice were treated i.p. with PBS or 200 µg of anti-CD4 (clone GK1.5), anti-CD8 (clone 483 
53-6.72) or isotype control antibodies (all from Bioxcell) every 3 days starting from cell challenge. 484 
In the therapeutic model, 1x10
4
 4T1 tumorsphere-derived cells were injected s.c. and the mice were 485 
vaccinated when the tumor had reached 2 mm mean diameter. s.c. tumor growth was reported as 486 
tumor volume. Mice were euthanized 20 days after cell challenge and lungs were removed 
7
. Right 487 
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lungs were fixed in 4%formaldehyde, paraffin embedded, sectioned and H&E stained. Slides were 488 
digitized using a PannoramicDesk scanner and analyzed with PannoramicViewer1.15.4 (3D 489 
HISTECH). Two sections of each lung were prepared. In order to avoid double counting of the 490 
same lesion, the average of the values obtained by analyzing the two sections was calculated and 491 
then reported. Metastases and total lung area were determined using PannoramicViewer and 492 
ImageJ, respectively. The remaining lobes were processed for FACS. 493 
Statistical analysis 494 
Student’s t-test was used. Data are shown as mean ± SEM unless otherwise stated. P <0.05 was 495 
considered significant.  496 
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Figure Legends 663 
Figure 1. Generation of BoHV-4-mxCT. A) Diagram (not to scale) showing the retargeting event 664 
obtained by heat-inducible homologous recombination in SW102 E. coli containing pBAC-BoHV-665 
4-A-TK-KanaGalK-TK, where the Kana/GalK cassette was replaced with the CMV-mxCTgD106 666 
expression cassette flanked by BoHV-4 TK sequences, located in pINT2 shuttle plasmid vector. B) 667 
Representative 2-deoxy-galactose resistant colonies tested by HindIII restriction enzyme analysis, 668 
agar gel electrophoresis and Southern blotting performed with a specific probe for the mxCT ORF. 669 
The 2,650 bp band (blue circle), corresponding to the un-retargeted pBAC-BoHV-4-A-TK-670 
KanaGalK-TK control, has been replaced by a 3156 bp band (red circle) in pBAC-BoHV-4-A-671 
CMV-mxCTgD106ΔTK. C) Representative phase contrast and fluorescent microscopic images of 672 
plaque formed by viable reconstituted recombinant BoHV-4-mxCT after the corresponding BAC 673 
DNA electroporation into BEK cells expressing cre recombinase (Magnification, 10X). D) 674 
Replication kinetics of BoHV-4-mxCT growth on BEK cells compared with the parental BoHV-4-675 
A isolate. The data presented are the means ± SEM of triplicate measurements (P>0.05 for all time 676 
points as measured by Student's t-test). E) Western immunoblotting of cells infected with BoHV-4-677 
mxCT or the parental BoHV-4-A used as a negative control. The lanes were loaded with different 678 
amounts of total protein cell extracts (5, 10 and 20 μl). 679 
Figure 2. BoHV-4-mxCT vaccination induces an anti-xCT humoral response. Sera from 680 
untreated (white bars), BoHV4-A29- (gray bars), and BoHV-4-mxCT- (black bars), vaccinated 681 
mice were tested by ELISA on wells coated with A) full-length mouse xCT protein, or peptides 682 
corresponding to mouse xCT extracellular loops B) 1, C) 2, D) 3, E) 4 or F) 6. Graphs show mean ± 683 
SEM of sera pooled from 3 independent experiments. In A, antibody concentration was calculated 684 
based on a standard curve obtained with a commercial anti-xCT antibody targeting its N-terminal 685 
region. G) Representative immunofluorescence images of dissociated 4T1 tumorsphere cells 686 
incubated with sera of vaccinated mice. The specific signal (green), was detected using an Alexa 687 
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Fluor488-conjugated anti-mouse secondary antibody. Nuclei were counterstained with DAPI (blue). 688 
Magnification 40X, Scale bar, 40 µm. **, P < 0.01, Student’s t-test. H) ADCC assay performed 689 
using CFSE
+ 
4T1 target cells incubated with 1:50 pooled sera from untreated, BoHV4-A29- and 690 
BoHV-4-mxCT-vaccinated mice and splenocytes from untreated mice as effector cells at different 691 
effector/target cells ratios (200:1, 100:1, and 50:1). Results shown are the mean ± SEM of the 692 
percentage of ADCC, calculated as in Material and Methods. 693 
Figure 3. BoHV-4-mxCT induces antibodies to target CSC and affects self-renewal and ROS 694 
flux. TUBO A-L)- and 4T1 M-P)-derived tumorspheres were incubated for 5 days with medium, 695 
sera of BALB/c untreated BoHV-4-A29- and BoHV-4-mxCT-vaccinated mice, or with SASP (50 696 
M). A) Representative images of tumorspheres, magnification 40X, scale bar 40 µm. B) Sphere 697 
generating ability reported as tumorsphere number/10
3
 plated cells. C) Sphere diameter measured 698 
with the AxioVision 4.8 software. D) Percentage of cells in the different phases of the cell cycle, as 699 
measured by FACS analysis using propidium iodide E-F) Aldefluor positivity reported as 700 
percentage of positive cells or as representative density plots. G-H) FACS analysis of ROS 701 
production, reported as DCF MFI or shown as representative histograms. I-L) Real time PCR of the 702 
ferroptosis marker Chac1 or of xCT. All graphs show mean ± SEM from at least three independent 703 
experiments. M) Sphere generating ability reported as tumorsphere number/10
3
 plated cells. N) 704 
FACS analysis of ROS production, reported as DCF MFI. O) Aldefluor positivity reported as 705 
percentage of positive cells. P) Evaluation of glutamate in the supernatants of treated 4T1 706 
tumorspheres or of parental 4T1 cells cultured as monolayers.  *, P < 0.05; **, P < 0.01, ***, P < 707 
0.001, Student’s t-test. 708 
Figure 4. Vaccination with BoHV-4-mxCT decreases mammary cancer lung metastases. A-D) 709 
BALB/c mice were vaccinated twice with BoHV-4-mxCT, BoHV-4-A29 or left untreated. One 710 
week after the final administration, TUBO-derived tumorspheres were injected into the tail vein of 711 
treated mice. 20 days after cell challenge, lungs were removed, sectioned and micrometastasis 712 
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number was determined in at least 2 H&E sections per mouse. A) Photograph of representative 713 
lungs, B) Representative images of lung metastases after H&E staining. Graphs showing C) the % 714 
of metastatic area and D) metastases number per square mm (sq mm), measured in mouse lungs 715 
from 3 independent experiments. E-H) BALB/c mice were s.c. challenged with 1 x 10
4 
4T1 716 
tumorsphere-derived cells. When the tumors reached 4 mm diameter, mice were vaccinated and 717 
boosted 14 days later. E) Subcutaneous tumor diameters were measured at the indicated time points 718 
and tumor volume was calculated. Graphs showing F) the % of metastatic area and G) the number 719 
of metastases per square mm measured in lungs. H) Representative images of lung metastases after 720 
H&E staining. *P<0.05, **P<0.01, Student's t-test.  721 
Figure 5. BoHV-4-mxCT induces lung T lymphocyte activation in vaccinated mice. 722 
Cytofluorimetric analysis of lung immune infiltrates in untreated (white bars), BoHV4-A29- (gray 723 
bars) and BoHV-4-mxCT- (black bars), vaccinated mice. A) Graph shows the percentage ± SEM of 724 
CD45
+
 myeloid cells expressing the markers of mMDSC (CD11b
+
Ly6C
+
), neutrophil/gMDSC 725 
(CD11b
+
Ly6G
+
), macrophage (CD11b
+
F4/80
+
), and dendritic cell (CD11b
−
CD11c
+
), populations. 726 
B) Graph shows the percentage ± SEM of CD45
+
 cells expressing the markers of T (CD3
+
CD49b
-
), 727 
and NK (CD3
−
CD49b
+
), populations. C) Percentage ± SEM of CD4
+
 or CD8
+
 cells among the 728 
CD45
+
CD3
+
 T cell population. D) Percentage ± SEM of CD69
+
 cells among total T, CD4
+
 or CD8
+
 729 
T, and NK cell populations. E) Percentage ± SEM of PD1
+
 cells among total T, CD4
+
 or CD8
+
 T, 730 
and NK cell populations. F) Percentage ± SEM of PDL1
+
 cells among epithelial (CD45
-
) or 731 
myeloid (CD11b
+
) cells. G-H) Representative density plots showing G) CD3 and CD49b 732 
expression on CD45
+
 cells, and H) CD69 and PD1 expression on CD4
+
 or CD8
+
 T lymphocytes . *, 733 
P < 0.05; **, P < 0.01, ***, P < 0.001, Student’s t-test.  734 
Figure 6. BoHV-4-mxCT vaccination induces degranulation and IFN- production in T 735 
lymphocytes. A-N) Splenocytes from untreated (white bars), BoHV4-A29- (gray bars), and BoHV-736 
4-mxCT- (black bars), vaccinated mice, were co-cultured with mitomycin C treated 4T1 cells 737 
31 
 
overnight (A-F) or for 5 days (G-N), incubated with antibodies against CD107a and b FITC in the 738 
presence of Brefeldin A for 4 hours, then stained with antibodies against CD45, CD4, CD8, and 739 
CD69 and for intracellular IFN- and analyzed by FACS. Graphs show means ± SEM of the 740 
percentages of A-C, G-I) CD4
+
 or D-F, L-N) CD8
+
 cells expressing A, D, G, L) CD69, B, E, H, 741 
M) IFN- or C, F, I, N) CD107 from three experiments. O) Splenocytes from untreated, BoHV4-742 
A29 and BoHV-4-mxCT vaccinated mice were co-cultured with CFSE
+
 4T1 cells for 48 hours, then 743 
the percentage of 7-AAD
+
 dead cells among the CFSE
+
 target populations was analyzed by FACS. 744 
Graphs shows mean ± SEM of the percentages of specific lysis, calculated as described in Material 745 
and Methods. *, P < 0.05; **, P < 0.01, ***, P < 0.001, Student’s t-test. 746 
Figure 7. Depletion of T lymphocytes impairs BoHV-4-mxCT anti-metastatic activity. A, B) 747 
BALB/c mice were vaccinated twice with BoHV-4-mxCT, BoHV-4-A29 or left untreated. One 748 
week after the final vaccination, TUBO-derived tumorspheres were injected intravenously. Mice 749 
were then treated i.p., every 3 days, with either PBS or 200 µg of anti-CD4, anti-CD8 or isotype 750 
control antibodies. 20 days after cell challenge, lungs were removed, sectioned and micrometastasis 751 
number was determined in H&E sections. Graphs showing means ± SEM of A) the % of metastatic 752 
area and B) metastasis number per square mm (sq mm) (n=5 per group). C) TUBO-derived 753 
tumorspheres were incubated for 5 days with medium, sera of untreated, BoHV-4-A29- or BoHV-4-754 
mxCT-vaccinated BALB/c mice, or with IgG purified from sera from BoHV-4-mxCT-vaccinated 755 
mice (50 g/ml). FACS analysis of MHC class I, MHC class II and Fas, reported as means ± SEM 756 
of MFI from three experiments. *, P < 0.05; **, P < 0.01, ***, P < 0.001, Student’s t-test. 757 







atggtcagaaagccagttgtggccaccatctccaaaggaggttacctgcagggcaatatg 
 M  V  R  K  P  V  V  A  T  I  S  K  G  G  Y  L  Q  G  N  M  
agcgggaggctgccctccatgggggaccaagagccacctgggcaggagaaggtagttctg 
 S  G  R  L  P  S  M  G  D  Q  E  P  P  G  Q  E  K  V  V  L  
aaaaagaagatcactttgctgaggggggtctccatcatcatcggcaccgtcatcggatca 
 K  K  K  I  T  L  L  R  G  V  S  I  I  I  G  T  V  I  G  S  
ggcatcttcatctcccccaagggcatactccagaacacgggcagcgtgggcatgtccctg 
 G  I  F  I  S  P  K  G  I  L  Q  N  T  G  S  V  G  M  S  L  
gttttctggtctgcctgtggagtactgtcactttttggagccctgtcctatgcagaatta 
 V  F  W  S  A  C  G  V  L  S  L  F  G  A  L  S  Y  A  E  L  
ggtacaagcataaagaaatctggtggtcattacacatacattctggaggtctttggtcct 
 G  T  S  I  K  K  S  G  G  H  Y  T  Y  I  L  E  V  F  G  P  
ttgctggcttttgttcgagtctgggtggaactgctcgtaatacgccctggagctactgct 
 L  L  A  F  V  R  V  W  V  E  L  L  V  I  R  P  G  A  T  A  
gtgatatccctggcatttggacgctacatcctggaaccattttttattcaatgtgaaatt 
 V  I  S  L  A  F  G  R  Y  I  L  E  P  F  F  I  Q  C  E  I  
cctgaacttgcaatcaagctcgtgacagctgtgggcatcactgtggtgatggtcctaaat 
 P  E  L  A  I  K  L  V  T  A  V  G  I  T  V  V  M  V  L  N  
agcacgagtgtcagctggagtgcccggatccagattttcctaaccttttgcaagctcaca 
 S  T  S  V  S  W  S  A  R  I  Q  I  F  L  T  F  C  K  L  T  
gcaattctgataattatagtccctggagttatacagctaattaaagggcaaacacatcac 
 A  I  L  I  I  I  V  P  G  V  I  Q  L  I  K  G  Q  T  H  H  
tttaaagatgcattttcaggaagagacacaagtctaatggggttgcccttggctttttat 
 F  K  D  A  F  S  G  R  D  T  S  L  M  G  L  P  L  A  F  Y  
tatgggatgtatgcatatgctggctggttttacctcaactttattactgaagaagtagac 
 Y  G  M  Y  A  Y  A  G  W  F  Y  L  N  F  I  T  E  E  V  D  
aaccctgaaaaaaccatcccccttgcaatctgcatctccatggctatcatcacagtgggc 
 N  P  E  K  T  I  P  L  A  I  C  I  S  M  A  I  I  T  V  G  
tacgtactgacaaacgtggcctattttaccaccatcagtgcggaggagctgctgcagtcc 
 Y  V  L  T  N  V  A  Y  F  T  T  I  S  A  E  E  L  L  Q  S  
agcgccgtggcggtgaccttctctgagcggctgctgggaaaattctcattagcagtcccg 
 S  A  V  A  V  T  F  S  E  R  L  L  G  K  F  S  L  A  V  P  
atctttgttgccctctcctgcttcggctccatgaacggtggtgtgttcgctgtctccagg 
 I  F  V  A  L  S  C  F  G  S  M  N  G  G  V  F  A  V  S  R  
ttattctacgtcgcatctcgagaagggcaccttccggaaatcctctctatgattcatgtc 
 L  F  Y  V  A  S  R  E  G  H  L  P  E  I  L  S  M  I  H  V  
cacaagcacactcctctgccagctgttattgttttgcatcctctgacgatggtgatgctc 
 H  K  H  T  P  L  P  A  V  I  V  L  H  P  L  T  M  V  M  L  
ttctccggagacctctatagtcttctaaatttcctcagttttgccaggtggctttttatg 
 F  S  G  D  L  Y  S  L  L  N  F  L  S  F  A  R  W  L  F  M  
gggctggcagtcgcaggactgatttatcttcgatacaaacgcccagatatgcatcgtcct 
 G  L  A  V  A  G  L  I  Y  L  R  Y  K  R  P  D  M  H  R  P  
ttcaaggtgcctctcttcatcccggcactattttccttcacctgcctcttcatggttgtc 
 F  K  V  P  L  F  I  P  A  L  F  S  F  T  C  L  F  M  V  V  
ctctctctttactcggacccattcagcaccggggtcggttttcttatcaccttgactggg 
 L  S  L  Y  S  D  P  F  S  T  G  V  G  F  L  I  T  L  T  G  
gtccctgcatattatctcttcattgtatgggacaagaaacccaagtggttcagacgatta 
 V  P  A  Y  Y  L  F  I  V  W  D  K  K  P  K  W  F  R  R  L  
tcagacagaataaccagaacattacagattatactagaagttgtaccagaagactctaaa 
 S  D  R  I  T  R  T  L  Q  I  I  L  E  V  V  P  E  D  S  K  
gaattagtcgactactggttcatgcgccacgggggcgtcgttccgccgtattttgaggag 
 E  L  V  D  Y  W  F  M  R  H  G  G  V  V  P  P  Y  F  E  E  
tcgaagggctacgagccgccgcctgccgccgatgggggttccccctaa 
 S  K  G  Y  E  P  P  P  A  A  D  G  G  S  P  -   
 
Supplementary Figure 1. A) Mouse xCT (yellow) tagged (red) ORF with deduced amino acids 
sequence. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S2. pINT2-CMV-mxCTgD106 induces xCT expression. pINT2-CMV-
mxCTgD106 shuttle vector or mock control vector were transiently transfeced into HEK 293T cells. 
Western immunoblotting of different amounts of total protein cell extracts (5, 10 and 15 μl) using a 
monoclonal antibody directed against the gD106 tag.  
 
Mouse xCT 
5      10      15 ul of cellular extract 5      10      15 
Mock pINT2mxCT 
59 kd 
 Supplementary Figure S3. BoHV-4-mxCT-induced antibodies affect self-renewal and ROS 
flux in human CSC. A) Sera from untreated (white bars), BoHV4-A29- (gray bars), and BoHV-4-
mxCT- (black bars) vaccinated mice were tested by ELISA on wells coated with full-length human 
xCT protein. Antibody concentration was calculated based on a standard curve obtained with a 
commercial anti-xCT antibody targeting its N-terminal region. Graph shows mean ± SEM of sera 
pooled from 3 independent experiments. B) FACS analysis of xCT expression on tumorspheres 
generated from Her2
+
 human SKBR3 cells stained with control Ig (gray histogram) or rabbit anti-
xCT (black histrogram). C-E) SKBR3-derived tumorspheres were incubated for 5 days with 
medium, sera of BALB/c mice left untreated or vaccinated with BoHV-4-A29 or BoHV-4-mxCT, 
or with SASP (50 M). C) Sphere generating ability reported as tumorsphere number/103 plated 
cells. D, E) FACS analysis of ROS production, reported as DCF MFI or shown as representative 
histograms. 
 
